Masthead
Who writes PeptideRank
3 editors, split by what each piece is actually about. No external party contributes copy, and nothing here is written by a company that sells what it describes — see the editorial policy for the full method.
Marcus Webb researches and verifies peptide and GLP-1 telehealth provider pricing for PeptideRank, checking every claim against the provider's own published terms.
- peptide therapy
- GLP-1 receptor agonists
- growth-hormone secretagogues
- compounded pharmacy regulation
- telehealth pricing transparency
Naomi Ellis covers how peptide and GLP-1 therapies affect women specifically — menstrual cycle, PCOS, pregnancy and breastfeeding contraindications, and reported effects on breast and vaginal tissue — reading the underlying trial or case-report data rather than repeating what a forum thread claims it says.
- GLP-1 receptor agonists in women
- PCOS and metabolic therapy
- menstrual cycle effects of rapid weight loss
- pregnancy and lactation contraindications
- peptide therapy safety data
David Chen tracks FDA compounding and approval status and reviews the published mechanism and outcome data behind each peptide this site covers, tracing every figure back to the trial or agency filing that produced it.
- FDA compounding regulation (503A/503B)
- GLP-1 and growth-hormone secretagogue clinical trials
- drug shortage and approval status tracking
- peptide pharmacology
Published by David
- Is Compounded Tirzepatide Still Legal? What the FDA Actually Says
- Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows
- Retatrutide: What's Actually Approved, What's Actually Known, and What It Actually Costs Right Now
- Sermorelin Before and After: What the Evidence Actually Shows You Can Expect
- Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Actually Show
- Retatrutide Dosing: The Doses and Titration Schedules Actually Tested in Its Clinical Trials
- Retatrutide Side Effects: What Its Clinical Trials Have Actually Reported